Education
About Us
Working with TipRanks
Follow Us
Biotricity Inc (BTCY)
OTHER OTC:BTCY
Top Page
Biotricity
(OTC:BTCY)
Rating:45Neutral
Price Target:―
Positive Factors
Gross Margin
Gross margin expanded to 80.4% driven by an 84% subscription mix that captures the scale benefits of fixed cloud-hosting and cellular data contracts.
Patent Acquisition
Patent acquisition enhances Biotricity’s competitive profile in multi-sensor monitoring.
Product Innovation
Product innovation remains a catalyst as the next-generation, cellular-enabled Biocore Pro gains traction, and strategic partnerships extend Biotricity’s remote monitoring algorithms into new markets.
Negative Factors
Neutral Rating
While there is stable growth and a bullish outlook, a Neutral rating is maintained as expansion consistency, initiative outcomes, and respective financial impact are monitored.
Small-Cap Risks
An investment in Biotricity is subject to the risks inherent in all small-cap companies, including dilution, end-market product acceptance and pricing, and competition against companies with greater resources.
Biotricity (BTCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.44M
Dividend YieldN/A
Average Volume (3M)43.65K
Price to Earnings (P/E)―
Beta (1Y)-0.32
Revenue Growth18.12%
EPS Growth86.52%
CountryUS
Employees55
SectorHealthcare
Sector Strength53
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.03
Shares Outstanding26,567,768
10 Day Avg. Volume34,078
30 Day Avg. Volume43,646
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.85
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit3.01
Enterprise Value/Ebitda-31.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Biotricity Business Overview & Revenue Model
Company DescriptionBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
How the Company Makes MoneyBiotricity makes money through the sale and leasing of its medical devices, primarily the Bioflux device, to healthcare providers, including hospitals and clinics. Revenue is generated from both the initial sale/lease of the device and ongoing service fees for data monitoring and analysis. The company may also engage in partnerships with healthcare organizations to expand its reach and enhance service offerings. Additionally, Biotricity may explore revenue opportunities through research and development collaborations in the medical technology sector.
Biotricity Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Positive
Biotricity showed significant advancements and strategic partnerships leading to revenue growth and reduced operating expenses, positioning the company close to profitability. Despite ongoing net losses and long sales cycles, the positive developments, such as international approvals and gross margin improvements, indicate a strong trajectory towards sustainable growth.Q4-2025 Updates
Positive Updates
Expansion of Cardiac AI Cloud Platform
Biotricity expanded its Cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google TensorFlow, leveraging over 1 trillion heartbeats of anonymized data. This platform aims to enhance diagnostic accuracy and improve patient outcomes.
Strategic Alliances with Group Purchasing Organizations (GPOs)
Biotricity formed partnerships with three major GPOs, allowing access to approximately 90% of hospitals in the U.S., significantly expanding market reach.
Revenue Growth
For the fourth quarter ended March 31, 2025, revenue increased by 16.5% year-over-year to $3.7 million, and for the fiscal year, revenue rose by 14.3% to $13.8 million.
Positive Adjusted EBITDA
Achieved positive adjusted EBITDA of $438,000 for the last quarter of fiscal 2025, indicating progress towards profitability.
Gross Profit and Margin Improvement
Gross profit for the quarter increased by 31% to $3 million, with a gross margin improvement of over 890 basis points to 80.4%.
Operating Expenses Reduction
Operating expenses for the fiscal year decreased by 24.5% to $13 million, with SG&A expenses down by 30.2% and R&D expenses reduced by 19.2%.
International Approvals and Expansion
Received Health Canada approval and regulatory approval in Saudi Arabia, opening new revenue streams in international markets.
Negative Updates
Net Loss
Net loss attributable to common stockholders for the fiscal year ended March 31, 2025, was $11.9 million, albeit an improvement from $14.9 million in the prior fiscal year.
Long Sales Cycles
Sales cycles with GPOs and hospitals are lengthy, with upwards of a year, which may delay acceleration in revenue growth.
Company Guidance
During the call, Biotricity provided guidance indicating a transformative fiscal year 2025, marked by strategic initiatives that have positioned the company near profitability and positive EBITDA. The company highlighted a significant 16.5% year-over-year increase in fourth-quarter revenue to $3.7 million and a 14.3% increase in fiscal year revenue to $13.8 million. Gross profit for the quarter rose by 31% to $3 million, with a gross margin improvement of over 890 basis points to 80.4%. Operating expenses decreased by 24.5% to $13 million for the fiscal year, contributing to a net loss reduction from $14.9 million to $11.9 million. The fourth quarter saw an adjusted EBITDA of $438,000, translating to $0.017 per share. Biotricity's strategic partnerships, FDA initiatives, and international market approvals, such as in Saudi Arabia, are expected to drive continued growth. The company's focus on economies of scale and expanding their AI-driven cardiac platform positions them for sustained profitability and expansion in 2026 and beyond.Biotricity Financial Statement Overview
Summary
Biotricity demonstrates robust revenue growth but struggles with profitability and financial stability. The high debt levels and negative equity raise concerns about long-term sustainability. While the company is expanding its top line, achieving profitability and strengthening the balance sheet are critical for future resilience.Income Statement
Biotricity shows a positive revenue growth trend with a 37.6% increase from 2023 to 2024 (TTM), indicating strong top-line expansion. However, the company faces substantial profitability challenges with persistently negative EBIT and net profit margins, reflecting ongoing operational inefficiencies and high costs relative to revenues.45
Neutral
Balance Sheet
The company's balance sheet reveals considerable financial strain. With a negative stockholders' equity and a high debt-to-equity ratio, Biotricity is highly leveraged, indicating potential solvency issues. The equity ratio is also negative, further highlighting financial instability and risk.30
Negative
Cash Flow
Biotricity's cash flow statement shows negative free cash flow, though there is a slight improvement in operating cash flow from previous periods. The operating cash flow to net income ratio is negative, suggesting cash generation challenges. However, positive financing cash flows indicate reliance on external funding to support operations.40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.46M | 13.79M | 12.06M | 9.64M | 7.65M | 3.38M |
| Gross Profit | 11.32M | 10.56M | 8.36M | 5.44M | 4.57M | 1.27M |
| EBITDA | -1.10M | -3.21M | -8.90M | -16.07M | -16.73M | -12.51M |
| Net Income | -5.40M | -8.42M | -14.09M | -18.66M | -29.13M | -15.49M |
Balance Sheet | ||||||
| Total Assets | 6.04M | 5.64M | 5.94M | 6.51M | 16.68M | 4.44M |
| Cash, Cash Equivalents and Short-Term Investments | 391.29K | 365.14K | 786.06K | 570.46K | 12.07M | 2.20M |
| Total Debt | 13.29M | 26.09M | 23.88M | 19.55M | 15.35M | 4.71M |
| Total Liabilities | 36.84M | 35.66M | 35.92M | 26.36M | 18.82M | 11.27M |
| Stockholders Equity | -30.80M | -30.01M | -29.98M | -19.85M | -2.14M | -6.83M |
Cash Flow | ||||||
| Free Cash Flow | -1.26M | -2.38M | -6.69M | -13.55M | -15.19M | -11.08M |
| Operating Cash Flow | -1.26M | -2.38M | -6.69M | -13.55M | -15.16M | -11.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -29.77K | 0.00 |
| Financing Cash Flow | 1.50M | 1.93M | 6.74M | 2.00M | 25.17M | 12.20M |
Biotricity Technical Analysis
Positive
0.69
Price Trends
0.48
Positive
0.48
Positive
0.44
Positive
Market Momentum
0.04
Negative
60.83
Neutral
69.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTCY, the sentiment is Positive. The current price of 0.69 is above the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.48, and above the 200-day MA of 0.44, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.83 is Neutral, neither overbought nor oversold. The STOCH value of 69.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BTCY.
Biotricity Risk Analysis
Biotricity disclosed 50 risk factors in its most recent earnings report. Biotricity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biotricity Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.95B | -0.40 | -42.50% | 2.21% | 22.29% | -1.85% | |
51 Neutral | $9.63M | 0.38 | -499.57% | ― | -73.36% | ― | |
47 Neutral | $9.38M | ― | -235.41% | ― | 0.36% | -17.20% | |
45 Neutral | $18.44M | ― | 42.40% | ― | 18.12% | 86.52% | |
45 Neutral | ― | ― | -48.61% | 32.18% | |||
45 Neutral | $11.93M | ― | -63.40% | ― | -91.14% | 9.47% | |
40 Underperform | $7.74M | ― | -92.99% | ― | -1.88% | 23.99% |
* Healthcare Sector Average
Performance Comparison
BTCY
Biotricity
0.71
0.34
91.89%
SSKN
Strata Skin Sciences
1.74
-1.51
-46.46%
NURO
Neurometrix
4.58
0.85
22.79%
BMRA
Biomerica
2.91
0.07
2.46%
CODX
Co-Diagnostics
0.31
-0.97
-75.78%
PAVM
PAVmed
0.44
-0.75
-63.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.